Latest News and Press Releases

Agios today announced financial results and updates for the third quarter ended September 30, 2025.

Agios today announced that the CHMP has adopted a positive opinion for the new indication for PYRUKYND in adults for anemia associated with thalassemia

New York, USA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Thalassemia Treatment Market to Witness Significant Growth by 2034 Driven by Novel Drug Development | DelveInsight The thalassemia market is...

Agios announced that the U.S. FDA has extended the PDUFA goal date for the sNDA of PYRUKYND for adults with thalassemia by three months to December 7, 2025

Agios Pharmaceuticals today announced that the Saudi Food and Drug Authority has approved PYRUKYND® for the treatment of adult patients with thalassemia

Agios Pharmaceuticals today announced financial results and updates for the second quarter ended June 30, 2025.

EXTON, PA, June 04, 2025 (GLOBE NEWSWIRE) -- Despite the promise of new curative strategies for beta thalassemia, such as Casgevy (Vertex) and Zynteglo (bluebird bio), most transfusion-dependent...

Agios Pharmaceuticals, Inc. today reported business highlights and financial results for the first quarter ended March 31, 2025.

NAGPUR, India, Nov. 14, 2024 (GLOBE NEWSWIRE) -- At the Haematocon 2024 conference in Nagpur, India, Hemex Health announced new product offerings for the Company’s Gazelle™ Diagnostic Device that...

New York , Jan. 16, 2024 (GLOBE NEWSWIRE) -- The global genetic testing market size is slated to expand at 9% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 45 billion...